OpGen > Investor Relations > 2016 Press Releases

2016 Press Releases

Keyword Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle  
12/19/2016OpGen Supports Passage of Landmark 21st Century Cures Act to Expedite Development of Solutions for Bacterial Infections
GAITHERSBURG, Md., Dec. 19, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) issued the statement below following the passage of the 21st Century Cures legislation in support for advancing medical breakthroughs to meet some of the biggest healthcare challenges today. The statement can be attributed to Evan Jones, Chairman and CEO of OpGen: “The passage of this historic legislation provides important improvements in the regulatory framework for drugs, diagnostics, and information products ... 
 Printer Friendly Version
12/16/2016OpGen Provides ATM Program Update
GAITHERSBURG, Md., Dec. 16, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) announces that during the fourth quarter of 2016 it has issued approximately 3.6 million shares of its common stock under its previously announced “at the market offering” program, resulting in aggregate net proceeds to the Company of approximately $4.6 million.  The proceeds will be used to support the company’s research, development and manufacturing of product candidates, and for other general corporate purposes.... 
 Printer Friendly Version
11/14/2016OpGen Collaborates With Merck to Develop Novel Rapid Diagnostics and Informatics Tools to Combat Antibiotic Resistance
GAITHERSBURG, M.d., Nov. 14, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced it has entered into a research collaboration with Merck, known as MSD outside the United States and Canada, to develop new rapid diagnostics and information technology products to help combat the threat of antimicrobial resistance. The companies will collaborate to support OpGen’s development of rapid DNA tests and a genomic knowledgebase of antibiotic-resistant pathogens for predicting antibiotic s... 
 Printer Friendly Version
10/27/2016Large Integrated Health Outcomes Study Reveals Shifting Epidemiology In Drug Resistant Organisms
SALT LAKE CITY and GAITHERSBURG, Md., Oct. 27, 2016 (GLOBE NEWSWIRE) -- A first-of-its-kind study of 900,000 hospital admissions from an integrated health system has yielded insights into shifts in the epidemiology of multi-drug resistant organisms (MDROs) in the community. New research, funded by OpGen (NASDAQ:OPGN) and conducted by Intermountain Healthcare and Enterprise Analysis Corporation (EAC) found that Methicillin Resistant Staphylococcus aureus (MRSA), Clostridium difficile (C. diffic... 
 Printer Friendly Version
10/26/2016OpGen’s Infectious Disease Portfolio Highlighted at IDWeek 2016
GAITHERSBURG, Md., Oct. 26, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that its infectious disease portfolio will be featured in one oral presentation and 5 poster sessions at IDWeek 2016, which takes place from October 26-30 in New Orleans, LA. The oral presentation, given by Jacqueline Reuben, Senior Infectious Disease Epidemiologist, District of Columbia Department of Health, will illustrate OpGen’s Acuitas Lighthouse® MDRO Management System capabilities in a regi... 
 Printer Friendly Version
10/24/2016OpGen Reports 2016 Third Quarter Financial Results and Provides Business Update
Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md., Oct. 24, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operational results for the three and nine months ended September 30, 2016. Highlights of the third quarter and recent weeks include: Third-quarter revenues of $0.8 million, a 23% decrease over prior year Nine-month revenues of $3.0 million, a 65% increase over prior year Automated QuickFISH® Pathogen ID clinical trial ... 
 Printer Friendly Version
10/19/2016OpGen Announces Date of Third Quarter 2016 Financial Results Conference Call
GAITHERSBURG, Md., Oct. 19, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its third quarter 2016 financial results after close of market on Monday, October 24, 2016. Following the announcement, OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company’s financial results and business progress. Dial-in Information U.S. Dial-In Number: 844-420-8185 International Dial-In Number: 216-562-0481 ... 
 Printer Friendly Version
09/08/2016OpGen, Inc. to Host Anti-Infectives Roundtable at the World Anti-Microbial Resistance Congress
GAITHERSBURG, Md., Sept. 08, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will participate in the World Anti-Microbial Resistance Congress being held September 8-9 in Washington, D.C. OpGen CEO Evan Jones will lead a presentation titled “Harnessing the power of informatics and genomic analysis to provide complete MDRO solutions” on Thursday, September 8 at 3:05 p.m. ET. OpGen will also host a roundtable discussion called “Antibiotic resistant bacteria in our In... 
 Printer Friendly Version
09/07/2016OpGen to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
GAITHERSBURG, Md., Sept. 07, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) an informatics and genomic analysis company, announces that Evan Jones, the Company’s Chairman and Chief Executive Officer, will provide a corporate update at the Rodman & Renshaw 18th Annual Global Investment Conference.  Mr. Jones’ presentation will be on Monday, September 12, 2016 at 3:25 p.m. Eastern time. The conference is being held from September 11 to 13 in New York City. To listen to the presentatio... 
 Printer Friendly Version
08/09/2016OpGen Reports 2016 Second Quarter Financial Results and Provides Business Update
Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md., Aug. 09, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today reported financial and operational results for the three and six months ended June 30, 2016. Highlights of the second quarter and recent weeks include: Achieved second quarter revenue of $1.2 million, 215% year over year growth Completed Intermountain Healthcare Retrospective MDRO Health Outcome Study Closed $10.4 million private placement ... 
 Printer Friendly Version
08/08/2016OpGen Announces Completion of the Intermountain Healthcare Retrospective MDRO Health Outcome Study
Study is the largest of its kind ever conducted in an integrated health system GAITHERSBURG, Md., Aug. 08, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), an informatics and genomic analysis company, announces the completion of its multi-drug resistant organisms (MDRO) health outcomes study with Intermountain Healthcare. It was a collaboration between Intermountain Healthcare and Enterprise Analysis Corporation (EAC) in a retrospective study to explore multi-drug resistant organisms and C... 
 Printer Friendly Version
08/02/2016OpGen, Inc. Announces Timing for Second Quarter Financial Results and Conference Call
GAITHERSBURG, Md., Aug. 02, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that financial results for the company’s second quarter ended June 30, 2016 will be released Tuesday, August 9, 2016. The management team will host a conference call discussing the company’s financial results and recent developments that day at 4:30 p.m. E.T. The call may be accessed by dialing (888) 883-4599 (domestic) or (484) 653-6821 (international) five minutes prior to the start of the call ... 
 Printer Friendly Version
06/20/2016OpGen Highlights Strong Performance of Acuitas® Resistome Test at ASM Microbe 2016
Test enables rapid and comprehensive genotyping of MDRO isolates GAITHERSBURG, Md., June 20, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today presented data that support the use of its Acuitas® Resistome Test in epidemiological studies to aid in routine evaluations for mechanisms of resistance among carbapenem resistant Enterobacteriaceae (CRE) at ASM Microbe 2016 in Boston. T... 
 Printer Friendly Version
06/02/2016OpGen to Present at the 6th Annual LD Micro Invitational Conference
GAITHERSBURG, Md. (June 2, 2016) – OpGen, Inc. (NASDAQ: OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announced today that Kevin Krenitsky, president, will present at the 6th Annual LD Micro Invitational conference on June 7, 2016 at 2:30 p.m. Pacific Time. The conference is being held from June 7- 9 at the Luxe Sunset Boulevard Hotel in Los Angeles.A webcast of the presentation will be available in the investor relations ... 
 Printer Friendly Version
05/20/2016OpGen Announces Closing of $10 Million Private Placement
GAITHERSBURG, Md., May 20, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the first closing of a private placement financing raising gross proceeds of $10.4 million.  The Company will use the net proceeds, after payment of offering expenses, to support the sales and marketing and continued research and development of the Company’s rapid diagnostic and Acuitas Lighthouse™ bio... 
 Printer Friendly Version
05/17/2016OpGen Supports New White House National Microbiome Initiative
Initiative to Foster a Needed Integrated Study of Microbiomes Across Various Ecosystems GAITHERSBURG, Md., May 17, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a leading developer of precision medicine tools to combat infectious disease in global healthcare settings, supports the new White House National Microbiome Initiative (NMI) and its more than $121 million of strategic investments from various Federal agencies into interdisciplinary and multi-ecosystem microbiome research and too... 
 Printer Friendly Version
05/12/2016OpGen Reports 2016 First Quarter Financial Results and Business Update
First quarter revenue increases 128% over prior year to $1.1 million First U.S. citywide quantification of Superbug pathogens completed in District of Columbia Announced pricing of $10.4 million private placement financing Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md., May 12, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today reported financial and ... 
 Printer Friendly Version
05/12/2016OpGen Announces Pricing of $10 Million Private Placement
GAITHERSBURG, Md., May 12, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the pricing of a private placement of units, each unit consisting of one share of common stock and one warrant to purchase 0.75 of one share of common stock, for an aggregate issuance of 9,053,556 shares of common stock and warrants to purchase 6,790,169 shares of common stock. Each unit will be sold a... 
 Printer Friendly Version
05/10/2016OpGen, Inc. Announces Timing for First Quarter Financial Results and Conference Call
GAITHERSBURG, Md., May 10, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today announced that financial results for the company’s first quarter ended March 31, 2016 will be released Thursday, May 12, 2016. The management team will host a conference call discussing the company’s financial results and recent developments that day at 4:30 p.m. E.T.  The call may be accessed by dialing (... 
 Printer Friendly Version
05/04/2016OpGen and District of Columbia Hospital Association Complete First Citywide Quantification of Multidrug-Resistant Organism (MDRO) Prevalence in Washington, D.C.-based Healthcare Facilities
Consortium of Washington, D.C. Health Organizations and OpGen test over 1,000 patient samples for antibiotic resistant bacteria OpGen’s Acuitas® detection technology provides surveillance to put city ahead of MDROs and leads to proactive intervention protocols GAITHERSBURG, Md. and WASHINGTON, May 04, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) and the District of Columbia Hospital Association (DCHA) today announced the completion of a citywide evaluation with Washington, D.C.’s pu... 
 Printer Friendly Version
05/02/2016OpGen Appoints Harry J. D'Andrea to Board of Directors
GAITHERSBURG, Md., May 02, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces the appointment of Harry J. D’Andrea to the company’s board of directors, effective April 29, 2016.  He will serve as a member of the board’s audit committee and will stand for reelection for a one-year term at the company’s annual meeting of stockholders, to be held June 22, 2016.    Mr. D’Andrea b... 
 Printer Friendly Version
04/11/2016New Study Data Show OpGen’s QuickFISH® Blood Culture Pathogen ID Tests to be Rapid and Cost-Effective, with Utility to Inform Antimicrobial Stewardship Decisions
Company to preview automated QuickFISH Digital Imager at 26th European Congress of Clinical Microbiology and Infectious Diseases GAITHERSBURG, Md., April 11, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today announced that new study data on its QuickFISH® tests were presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held from Ap... 
 Printer Friendly Version
03/30/2016OpGen Announces 2015 Fourth Quarter and Full Year Financial Results
Fourth quarter revenue increases 18% over prior year period to $1.3 million Conference call begins at 10:00 a.m. Eastern time today GAITHERSBURG, Md., March 30, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today reported financial and operational results for the fourth quarter and year ended December 31, 2015. OpGen reported total revenue for the fourth quarter of 2015 of $1.3 m... 
 Printer Friendly Version
03/21/2016OpGen Announces New Members to its Clinical Advisory Board
Adds leaders in infectious disease, antibiotic resistance and genetic analysisGAITHERSBURG, Md., March 21, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc.(NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announced that four new members have joined its Clinical Advisory Board (CAB). Joining the board are Debra A. Goff, Pharm.D., FCCP, Dag Harmsen, M.D., Stefan Riedel, M.D. Ph.D., D(ABMM), FCAP, and... 
 Printer Friendly Version
03/16/2016OpGen, Inc. Announces Timing for 2015 Fourth Quarter and Year End Financial Results and Conference Call
GAITHERSBURG, Md., March 16, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, today announced that financial results for the company’s fourth quarter ended December 31, 2015 will be released Wednesday, March 30, 2016. The management team will host a conference call discussing the company’s financial results and recent developments that day at 10:00 a.m. E.T.  The call may be accessed by... 
 Printer Friendly Version
02/03/2016OpGen to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
GAITHERSBURG, Md., Feb. 03, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a precision medicine company using molecular diagnostics and bioinformatics to combat infectious disease, announces that Evan Jones, the Company’s Chairman and Chief Executive Officer, will present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference on February 11, 2016 at 2:45 p.m. Eastern time. The conference is being held from February 10 to 11 in New York City. To listen to the present... 
 Printer Friendly Version
01/13/2016OpGen, Inc., to Present at Noble Financial Capital Markets’ 12th Annual Investor Conference
GAITHERSBURG, Md., Jan. 13, 2016 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN), a molecular diagnostics and bioinformatics company helping to guide antibiotic therapy and to assist healthcare providers in combatting multi-drug resistant infections, announced today that Chairman and Chief Executive Officer Evan Jones will present at the NobleCon12 - Noble Financial Capital Markets’ 12th Annual Investor Conference on January 20, 2016, at 10:30 a.m. Eastern Standard Time. The conference is being ... 
 Printer Friendly Version